Initial response to sorafenib by using enhancement criteria in patients with hepatocellular carcinoma.

about

Decrease in tumor enhancement on contrast-enhanced CT is associated with improved survival in patients with hepatocellular carcinoma treated with Sorafenib.

P2860

Q40693959-74239162-BA0F-4225-89D2-72D30E576C9D

P2860

Initial response to sorafenib by using enhancement criteria in patients with hepatocellular carcinoma.

Item

http://www.wikidata.org/entity/Q40707153

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

2013年论文

@zh

2013年论文

@zh-cn

name

Initial response to sorafenib ...... with hepatocellular carcinoma.

@en

type

Item

label

Initial response to sorafenib ...... with hepatocellular carcinoma.

@en

prefLabel

Initial response to sorafenib ...... with hepatocellular carcinoma.

@en

P1476

Initial response to sorafenib ...... with hepatocellular carcinoma.

@en

P2093

Akinobu Tawada

http://www.w3.org/2001/XMLSchema#string

Eiichiro Suzuki

http://www.w3.org/2001/XMLSchema#string

Fumihiko Kanai

http://www.w3.org/2001/XMLSchema#string

Osamu Yokosuka

http://www.w3.org/2001/XMLSchema#string

Sadahisa Ogasawara

http://www.w3.org/2001/XMLSchema#string

Tenyu Motoyama

http://www.w3.org/2001/XMLSchema#string

Tetsuhiro Chiba

http://www.w3.org/2001/XMLSchema#string

Yoshihiko Ooka

http://www.w3.org/2001/XMLSchema#string

P2860

Management of hepatocellular carcinoma: An update

Global cancer statistics, 2002

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Sorafenib in advanced hepatocellular carcinoma

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

Sorafenib in advanced clear-cell renal-cell carcinoma

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver

P2888

s12072-013-9425-4

P304

703-713

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S12072-013-9425-4

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2013-02-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26201804

http://www.w3.org/2001/XMLSchema#string

Initial response to sorafenib by using enhancement criteria in patients with hepatocellular carcinoma.

about

P2860

P2860

Initial response to sorafenib by using enhancement criteria in patients with hepatocellular carcinoma.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P698